er every three weeks being comparable to once weekly administration with respect to the incidence of subjects receiving at least one red blood cell transfusion from week 5 to the end of treatment phase. ng In a prospective, randomised double-blind, placebo-controlled study conducted in 344 anaemic lo patients with lymphoproliferative malignancies receiving chemotherapy there was a significant reduction in transfusion requirements and an improvement in haemoglobin response (p < 0.001). no
Σε μία προοπτική, τυχαιοποιημένη, διπλά τυφλή, ελεγχόμενη με εικονικό φάρμακο μελέτη που διεξήχθη σε 344 ασθενείς με αναιμία που πάσχουν από λεμφοϋπερπλαστικές κακοήθειες και όν